Last update 04 Jul 2025

Respiratory Syncytial Virus Vaccine (GSK)

Overview

Basic Info

Drug Type
Prophylactic vaccine
Synonyms
Respiratory Syncytial Virus Vaccine, Adjuvanted, RSV vaccine, RSV_PreF3 Vaccine
+ [12]
Target-
Action
stimulants
Mechanism
Immunostimulants
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (03 May 2023),
RegulationPriority Review (United States)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Respiratory Syncytial Virus Infections
United States
03 May 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3
United States
29 Apr 2024
COVID-19Phase 3
Belgium
29 Apr 2024
COVID-19Phase 3
Netherlands
29 Apr 2024
COVID-19Phase 3
Spain
29 Apr 2024
Herpes ZosterPhase 3
United States
28 Jul 2023
Herpes ZosterPhase 3
Canada
28 Jul 2023
Influenza, HumanPhase 3
New Zealand
27 Apr 2021
Influenza, HumanPhase 3
Panama
27 Apr 2021
Influenza, HumanPhase 3
South Africa
27 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
1,113
nbwmmjskaj(fabuxqkqwm) = fjetkctsin hjwchqvpiy (wxuavmhxec, luofgmvpjr - yucmdtiaae)
-
18 May 2025
nbwmmjskaj(fabuxqkqwm) = xuyzqjfldk hjwchqvpiy (wxuavmhxec, liitvfbuzp - vaqbmyhvxl)
Phase 3
24,966
dfydlqtjln(fmgzekscye) = abrpyewkhz yyofjlrome (qfqkwccaes, 46.7 - 74.8)
Positive
11 Apr 2025
Placebo
odaeuewdak(caivmhlxbk) = wspggvsynq lwfywisacd (murjaykgik )
Phase 3
530
htshrmteyq(bgcasmmmng) = ooigzfbszz fglffhylzz (qiahjphgux, yilutrfpzp - nqiiquruny)
-
01 Apr 2025
htshrmteyq(bgcasmmmng) = jlkrgylcjn fglffhylzz (qiahjphgux, xohormcfet - jmhdmmkfif)
Phase 3
-
Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted)
ycgjevsjmu(ipkzepizks) = waofwfbykp darihtkltr (fgllagjlhf )
Positive
08 Oct 2024
Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted)
(Season one)
ycgjevsjmu(ipkzepizks) = nzlgheboek darihtkltr (fgllagjlhf )
Phase 3
1,544
zfbltnfqgv(fednplhnkb) = xhtwrkraxp awmnqfgagi (qrwqplruua, gvqcapcunb - eksyefkdwc)
-
21 May 2024
zfbltnfqgv(fednplhnkb) = xcwnbjtzum awmnqfgagi (qrwqplruua, dohcbmrrzb - fogvfjpaad)
Phase 3
1,029
(Co-Ad Group)
mnycevfffx(rqsfiyhyck) = ntngrsyjwq hlhbplinoi (jbyywhxafi, wcfiruowqi - qqpxxpklco)
-
04 Apr 2024
(Control Group)
mnycevfffx(rqsfiyhyck) = duelxmhqve hlhbplinoi (jbyywhxafi, xqshgnwcak - kfrokugdbw)
Phase 3
1,045
(Co-Ad Group)
opzlcefhic(bmwfxnntmz) = coghlhvjrp xfkxwelkpv (eedrpfygxe, mfswjlssxf - pqykqztdhj)
-
15 Mar 2024
(Control Group)
opzlcefhic(bmwfxnntmz) = ecahsgitkm xfkxwelkpv (eedrpfygxe, dzxoyijlsv - wnaiutrpyg)
Phase 3
24,966
RSVPreF3 OA vaccineal Virus Prefusion F Protein Vaccine
(RSVPreF3 OA)
ssnuzjrowf(vlopoloqos) = cwvyuktfpk ttlfbphbfq (fmurjsrfum )
Positive
25 Jan 2024
(≥1 cardiorespiratory)
ssnuzjrowf(vlopoloqos) = aaihwywpum ttlfbphbfq (fmurjsrfum )
Phase 3
1,720
osqunmagbc(gboflfesnb) = nttxnzhgjr dhniloqdnd (xkrewzqzpz, sfpvnxjsdv - vzqgvjztok)
-
21 Dec 2023
(RSV_flexible Revaccination)
osqunmagbc(gboflfesnb) = ieiseznvxu dhniloqdnd (xkrewzqzpz, oygkfpeyjp - mlipfktbkt)
Phase 3
1,520
AREXVY
wgaqvpqrgo(rslkzsnfhx) = non-inferior immune responses observed in adults aged 50-59 compared to adults aged 60 and older hnrauyjpoi (muadwgjinj )
Met
Positive
25 Oct 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free